Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 12.55
NVIV's Cash to Debt is ranked lower than
54% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. NVIV: 12.55 )
Ranked among companies with meaningful Cash to Debt only.
NVIV' s Cash to Debt Range Over the Past 10 Years
Min: 0.11  Med: 53.60 Max: No Debt
Current: 12.55
F-Score: 3
Z-Score: -1.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -297.59
NVIV's ROE (%) is ranked lower than
95% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. NVIV: -297.59 )
Ranked among companies with meaningful ROE (%) only.
NVIV' s ROE (%) Range Over the Past 10 Years
Min: -775.86  Med: -546.32 Max: -195.09
Current: -297.59
-775.86
-195.09
ROA (%) -160.44
NVIV's ROA (%) is ranked lower than
92% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. NVIV: -160.44 )
Ranked among companies with meaningful ROA (%) only.
NVIV' s ROA (%) Range Over the Past 10 Years
Min: -1218.1  Med: -266.67 Max: 42.86
Current: -160.44
-1218.1
42.86
ROC (Joel Greenblatt) (%) -2562.54
NVIV's ROC (Joel Greenblatt) (%) is ranked lower than
72% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. NVIV: -2562.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVIV' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -13352.31  Med: -1292.80 Max: 334.39
Current: -2562.54
-13352.31
334.39
EBITDA Growth (3Y)(%) -33.30
NVIV's EBITDA Growth (3Y)(%) is ranked lower than
85% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. NVIV: -33.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVIV' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -62.2  Med: -33.30 Max: 543.1
Current: -33.3
-62.2
543.1
EPS Growth (3Y)(%) -32.30
NVIV's EPS Growth (3Y)(%) is ranked lower than
82% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. NVIV: -32.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVIV' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -61  Med: -32.30 Max: 490.5
Current: -32.3
-61
490.5
» NVIV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NVIV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.38
NVIV's P/B is ranked lower than
89% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. NVIV: 6.38 )
Ranked among companies with meaningful P/B only.
NVIV' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 67.4
Current: 6.38
0
67.4
EV-to-EBIT -2.43
NVIV's EV-to-EBIT is ranked lower than
99.99% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 20.72 vs. NVIV: -2.43 )
Ranked among companies with meaningful EV-to-EBIT only.
NVIV' s EV-to-EBIT Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: -2.43
EV-to-EBITDA -2.48
NVIV's EV-to-EBITDA is ranked lower than
99.99% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 18.13 vs. NVIV: -2.48 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVIV' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: -2.48
Current Ratio 4.11
NVIV's Current Ratio is ranked lower than
53% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. NVIV: 4.11 )
Ranked among companies with meaningful Current Ratio only.
NVIV' s Current Ratio Range Over the Past 10 Years
Min: 0.14  Med: 1.63 Max: 14.81
Current: 4.11
0.14
14.81
Quick Ratio 4.11
NVIV's Quick Ratio is ranked lower than
51% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. NVIV: 4.11 )
Ranked among companies with meaningful Quick Ratio only.
NVIV' s Quick Ratio Range Over the Past 10 Years
Min: 0.14  Med: 1.63 Max: 14.81
Current: 4.11
0.14
14.81

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.18
NVIV's Price/Net Cash is ranked lower than
56% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. NVIV: 7.18 )
Ranked among companies with meaningful Price/Net Cash only.
NVIV' s Price/Net Cash Range Over the Past 10 Years
Min: 4.72  Med: 18.36 Max: 48
Current: 7.18
4.72
48
Price/Net Current Asset Value 6.81
NVIV's Price/Net Current Asset Value is ranked lower than
57% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 7.24 vs. NVIV: 6.81 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NVIV' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 4.44  Med: 17.32 Max: 34.94
Current: 6.81
4.44
34.94
Price/Tangible Book 6.38
NVIV's Price/Tangible Book is ranked lower than
65% of the 1054 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. NVIV: 6.38 )
Ranked among companies with meaningful Price/Tangible Book only.
NVIV' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.83  Med: 14.49 Max: 29.7
Current: 6.38
3.83
29.7
Earnings Yield (Greenblatt) (%) -41.20
NVIV's Earnings Yield (Greenblatt) (%) is ranked lower than
82% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. NVIV: -41.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVIV' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -42.1  Med: 0.00 Max: 1000
Current: -41.2
-42.1
1000

More Statistics

EPS $ -1.48
Beta2.83
Short Percentage of Float12.41%
52-Week Range $3.90 - 17.87
Shares Outstanding(Mil)27.36

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
InVivo Therapeutics Holdings Corp. was incorporated on April 2, 2003, under the name of Design Source, Inc. The Company develops novel biomaterial technologies for the treatment of spinal cord injuries and hydrogels for therapeutics delivery. It is also developing an injectable, resorbable family of hydrogels for localized, controlled release of small molecules and proteins. Under the CMCC License, the Company has the right to sublicense the patents and have full control and authority over the development and commercialization of the licensed products, including clinical trials, manufacturing, marketing, and regulatory filings. The Comany also own the rights to the data generated pursuant to the CMCC License. The Company competes with major drug companies, specialized biotechnology firms, academic institutions, government agencies and private and public research institutions. The Company is subject to evolving federal, state and local environmental, health and safety laws and regulations.
» More Articles for NVIV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
InVivo Therapeutics Announces University of California San Diego Medical Center as New Site for... Feb 03 2016
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Regulation FD Disclosure Jan 11 2016
InVivo Therapeutics to Present at 8th Annual Biotech Showcase Jan 05 2016
InVivo Therapeutics to Present at 8th Annual Biotech Showcase Jan 05 2016
InVivo Therapeutics Announces Approval for INSPIRE Pivotal Probable Benefit Clinical Study of the... Jan 04 2016
InVivo Therapeutics Announces Approval for INSPIRE Pivotal Probable Benefit Clinical Study of the... Jan 04 2016
5 Stocks Ready for Breakouts Dec 18 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Regulation FD Disclosure Dec 17 2015
Promising Clinical Trials Coming in 2016 for IBD, Prostate Cancer and Spinal Cord Injuries Dec 15 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Financials Dec 08 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Regulation FD Disclosure Dec 03 2015
InVivo Therapeutics Announces Conditional Approval for INSPIRE Pivotal Probable Benefit Clinical... Dec 03 2015
Cambridge's InVivo advances plan to treat patients with chronic spine injuries Dec 02 2015
InVivo Continues to Rally With New SCI Treatment Strategy Dec 02 2015
InVivo Therapeutics Announces Bioengineered Neural TrailsTM Program for Chronic Spinal Cord Injury Dec 02 2015
InVivo Therapeutics Announces Bioengineered Neural Trails™ Program for Chronic Spinal Cord Injury Dec 02 2015
InVivo Therapeutics Announces Key Opinion Leader Event and Company Update with Robert Langer, ScD,... Dec 01 2015
InVivo Therapeutics Announces Key Opinion Leader Event and Company Update with Robert Langer, Sc.D.,... Dec 01 2015
Is Invivo Therapeutics Holdings Corp (NVIV) A Good Stock To Buy? Nov 27 2015
InVivo Therapeutics Announces Jay Blackington as New Vice President, Head of Human Resources Nov 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK